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http://breast-cancer-research.com/content/16/3/R59RESEARCH ARTICLE Open AccessA genomic analysis of mouse models of breast
cancer reveals molecular features of mouse
models and relationships to human breast cancer
Daniel P Hollern and Eran R Andrechek*Abstract
Introduction: Genomic variability limits the efficacy of breast cancer therapy. To simplify the study of the molecular
complexity of breast cancer, researchers have used mouse mammary tumor models. However, the degree to which
mouse models model human breast cancer and are reflective of the human heterogeneity has yet to be demonstrated
with gene expression studies on a large scale.
Methods: To this end, we have built a database consisting of 1,172 mouse mammary tumor samples from 26
different major oncogenic mouse mammary tumor models.
Results: In this dataset we identified heterogeneity within mouse models and noted a surprising amount of
interrelatedness between models, despite differences in the tumor initiating oncogene. Making comparisons
between models, we identified differentially expressed genes with alteration correlating with initiating events in
each model. Using annotation tools, we identified transcription factors with a high likelihood of activity within
these models. Gene signatures predicted activation of major cell signaling pathways in each model, predictions
that correlated with previous genetic studies. Finally, we noted relationships between mouse models and
human breast cancer at both the level of gene expression and predicted signal pathway activity. Importantly,
we identified individual mouse models that recapitulate human breast cancer heterogeneity at the level of gene
expression.
Conclusions: This work underscores the importance of fully characterizing mouse tumor biology at molecular,
histological and genomic levels before a valid comparison to human breast cancer may be drawn and provides
an important bioinformatic resource.Introduction
Breast cancer is a heterogeneous disease with significant
mortality associated with metastatic progression. Classifi-
cation subdivides human breast cancer into six categories
including Luminal A, Luminal B, HER2+, Basal, Claudin-
low and normal-like [1]. Recent work suggests additional
subclasses exist within each intrinsic subtype including
three basal subtypes with striking differences in overall
survival [2]. Further, The Cancer Genome Atlas (TCGA)
and the Encyclopedia of DNA Elements (ENCODE)
projects show remarkable variability in genetic alterations* Correspondence: andrech1@msu.edu
Department of Physiology, Michigan State University, 2194 Biomedical and
Physical Sciences Building, 567 Wilson Rd., East Lansing, MI 48864, USA
© 2014 Hollern and Andrechek; licensee BioM
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumbeyond gene expression both across and within subtypes
of human breast cancer. Together these genomic analyses
demonstrate the complex nature of human breast cancer.
To more readily study mechanisms leading to breast
cancer, research has turned to the mouse as a model.
Mouse models of breast cancer have employed various
methods of initiation, including mouse mammary tumor
virus (MMTV) infection, chemical mutagenesis and gen-
etically engineered mice (GEM). This pioneering work
identified and tested the role of many oncogenes in
breast cancer. With the insertion of MMTV into the
genome, numerous key oncogenes were uncovered
[3,4]. The later development of MMTV driven trans-
genics allowed for development of spontaneous models.
With the identification of human epithelial growth fac-
tor receptor 2 (HER2) amplification in human breasted Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pression of the activated rat form of HER2 (NeuNT)
resulted in breast cancer reinforced the importance of
HER2 as a driving oncogene [7]. More recently, models
have been refined to include tissue specific activation
resulting in gene amplification, analogous to human
HER2+ breast cancer [8], as well as temporal control
where transgene expression can be activated or inacti-
vated [9].
Individual mouse models have been used to model as-
pects of human breast cancer and the selection of the
appropriate model to compare to human breast cancer
has been directed by phenotype or known genetic events.
For instance, the MMTV-PyMT model is widely used to
examine metastasis [10] while P53 knockout mammary
epithelium transplanted into wild type hosts results in
tumors with various genetic mutations [11]. Another
aspect is the histological subtype associated with vari-
ous tumors in GEM models and the metastatic ability
can be altered with background [12]. Indeed, similar-
ities between mouse models such as Neu and Wnt as
well as their human counterparts have been previously
noted [13,14]. Importantly, in both human breast can-
cer and in many GEM models, there is significant
histological heterogeneity [15-17]. These attributes il-
lustrate the importance and utility of mouse models to
examine breast cancer.
With the number and variety of GEM models, it is im-
portant to consider how accurately these various systems
model human breast cancer. Initial studies using intrinsic
clustering revealed similarities between mouse models
and human breast cancer, albeit in a limited number of
samples [18]. Yet, a more detailed characterization of a
larger number of p53 null tumors revealed a variety of
subtypes with strong similarities to human breast can-
cer [11], revealing the importance of examining a large
number of samples to capture tumor heterogeneity
and variability. Further, expanding the number of Myc
induced tumors revealed that a subpopulation of Myc
induced tumors had similarities to claudin-low human
breast cancer [19]. Taken together, recent comparative
studies [11,17,19-22] highlighted a clear need for a
comprehensive examination of the genomic features of
mouse models of breast cancer and their relation to
human breast cancer. To this end, we assembled an ex-
pansive dataset of mouse models of breast cancer. This
dataset reveals the genomic heterogeneity of mouse
models and offers a predictive resource for essential
cell signaling pathways. Importantly, all comparisons
between all models are made available with our report.
These data demonstrate the similarities and differences
of the various subtypes of mouse models to the key
subtypes of human breast cancer and underscore the




Datasets (GSE10450, GSE11259, GSE13221, GSE13231,
GSE13259, GSE13553, GSE13916, GSE14226, GSE14457,
GSE14753, GSE15119, GSE15263, GSE15632, GSE15904,
GSE16110, GSE17916, GSE18996, GSE20465, GSE20614,
GSE21444, GSE22150, GSE22406, GSE23938, GSE24594,
GSE25488, GSE27101, GSE30805, GSE30866, GSE3165,
GSE31942, GSE32152, GSE34146, GSE34479, GSE6453,
GSE6581, GSE6772, GSE7595, GSE8516, GSE8828,
GSE8863, GSE9343, GSE9355 GSE37954, GSE2034,
GSE2603, GSE4922, GSE6532, AND GSE14020) were
downloaded from Gene Expression Omnibus. E-TABM-683
and E-TABM-684 were downloaded from Array Express.
For Affymetrix data, Bayesian Factor Regression Methods
(BFRM) [23] were used to combine datasets and remove
batch effects [24]. Agilent data was merged with Affymetrix
data using Chip Comparer [25] and Filemerger [26]. To
remove platform effects between Affymetrix and Agilent
data and batch effects between individual Agilent studies we
used COMBAT [27,28]. Batch effects and batch correction
were visualized by principle component analysis in Matlab
(for code see Additional file 1).
Data analysis
Unsupervised hierarchical clustering was done using Cluster
3.0 and exported using Java Tree View. The color scheme
for the heatmap and sample legends were made using
Matlab. Human breast cancer sample intrinsic subtypes
were classified according to protocol [1]. Prior to clus-
tering mouse models with human breast cancer, we
clustered the human breast tumor samples on their
own, to identify genes that would organize the breast tu-
mors according to their intrinsic subtype in the combined
dataset. We used these genes to filter the mouse and hu-
man combined gene expression dataset for unsupervised
hierarchical clustering.
Significance analysis of microarrays [29] was used for
fold change analysis. Settings for each comparison can be
found in the excel download for each model (Additional
files 2, 3). Gene ontology and TRANSFAC predictions were
made using GATHER [30]. Gene set enrichment analysis
was conducted using Genepattern [31]. The gene-set de-
scribing mammary cell-types was derived from [32].
Pathway activation was predicted according to previous
studies [2,33]. For mouse samples, specific conditions for
each pathway signature can be found in Additional file 4.
For human breast tumor samples, pathway activation was
predicted using Score Signatures [34] and conditions can
be found [2]. Mixture modeling was implemented accord-
ing to [2].
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Database assembly
We assembled a database containing 1,172 samples from
mouse mammary tumor models, cell types and normal
mammary gland. The major mouse models and descrip-
tions are listed in Table 1. Within a number of these models,
variants exist with different alleles, promoters, and genetic
backgrounds. In assembling the database, we measured the
non-biological variance between gene expression stud-
ies and batch correction with principle components
analysis (PCA) (Additional file 5A-D). PCA demonstrated
that normalization successfully removed artificial variance
between datasets (Additional file 5B,D). As a control, we
confirmed batch correction utilizing Neu-initiated tumorsTable 1 List of mouse models in the dataset
Model Arrays Promoter Description
Myc 319 MMTV WAP/Dox Myc mamma
and stability
Neu 124 MMTV Induction of




SV40 Large T Antigen 107 C3 WAP Induction of
breast cance
p53 92 Null Tumors with
CreEtv6/NTRK3 63 WAP Fusion onco
MET 52 MMTV Diverse histo
BRCA/p53 46 WAP MMTV BLG CKO of BRCA
basal breast
Wnt 35 MMTV Induction of
patterns.
IGF-IR 26 MTB Basal-like ma
claudin-low.
LPA 16 MMTV ER positive, m
Stat5 16 BLG Induction of
Brg1 (+/−) 14 Mutant Heterogeneo
DMBA 12 Chemical Mammary ca
squamous ce
Ras 10 MMTV Induction of
Int3 9 WAP Metastatic tu
RB/p107 7 CKO Adeno and a
basal.
APC CKO 6 K14-Cre CKO results i
heterogeneit
Autotaxin (ATX) 5 MMTV ER +metasta
BRCA 5 CKO Tumors simil
STAT1 5 Knockout ERa + PR+, h
Notch 4 Dox Induction of
PDK1 2 MMTV Induction of
Normal Mammary
Gland
47 Not Applicable Normal mam
genetic back
CKO, conditional knockout; Dox, doxacycline inducible MMTV-Rtta system; MMTV, mspanning the Affymetrix and Agilent platforms from sev-
eral studies. Prior to normalization (Additional file 5E)
PCA demonstrated that Neu tumors varied by platform.
After correction, Neu tumors clustered together in PCA,
demonstrating that artifactual variance has been removed
(Additional file 5F). With platform and batch effects
eliminated, we began to explore relationships in the
mouse model database.
Gene expression heterogeneity in mouse models
Using unsupervised hierarchical clustering, we examined
mouse mammary tumors initiated by various oncogenes.
Unsupervised hierarchical clustering generated four major
clusters (Figure 1A). We observed remarkable variabilityReferences
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erogeneity. For example, Myc initiated tumors span each
of the major clusters in the dendrogram. In contrast,
some models show uniformity in gene expression from
tumor to tumor, including Ras initiated tumors that
ordered into a single cluster. Interestingly, there was
significant interrelatedness between tumor models ini-
tiated with different oncogenes. Annotations for indi-
vidual tumors revealed that similarities in tumor histology
correlated with relationships in gene expression profiles. For
example, MMTV-Myc, MMTV-Met and a subset of 7,12-
dimethylbenz[a]anthracene (DMBA) induced tumors of the
adenosquamous histology shared gene expression profiles.
These data reveal mouse models with various levels of
heterogeneity and illustrate some of the tumor phenotypes
that drive relationships between different mouse models.
To define the characteristics of each cluster, we used
Significance Analysis of Microarrays (SAM) to identify dif-
ferentially regulated genes that define tumors within each
cluster (Additional file 6). We interrogated gene lists
for gene ontologies (Additional file 6). For instance,
Figure 1B shows the gene ontologies for the upregulated
genes in the blue cluster in Figure 1A. Ontological categor-
ies included genes involved in biological processes and me-
tabolism. To refine these results, tumors from each cluster
were examined with Gene Set Enrichment Analysis
(GSEA) (Additional file 7). Focusing on tumors in the
black cluster, GSEA showed enrichment for gene sets sep-
arating mesenchymal cells from luminal cells (Figure 1C,
Additional file 8A), including low expression of Zeb1 target
genes (Additional file 8B). Gene lists that define mammary
stem cells demonstrated that this cluster also had a gene
expression profile enriched for mammary stem cell-like
features (Additional file 8C,D). In agreement, the majority
of epithelial to mesenchymal transition (EMT) like tumors
were observed in the black cluster (Figure 1A, Additional
file 9). GSEA also demonstrated that tumors from the
other clusters had gene expression profiles consistent with
luminal cells (Additional file 10). For example, tumors
within the blue cluster correlated with gene signatures for
luminal progenitor cells and the orange cluster had similar-
ities in gene expression to mature luminal cells. Together,
these results define the characteristics of the tumors con-
tained in the major clusters.
Fold change analysis
Given that unique initiating events in the tumor models
should cause characteristic responses associated with the
tumor initiating event, we used SAM to identify genes sig-
nificantly altered within each model compared to all other
models (Additional file 2). Fold change differences were
also calculated between the tumors within a model and
normal mammary glands in the corresponding genetic
background (Additional file 3). As an example, wedetermined fold change gene expression differences for
Neu initiated tumors (Figure 2A). Collectively, SAM ana-
lysis provided a collection of genes that are differentially
expressed in each model.
To identify possible transcription factors that could be
active in mediating these gene expression changes, we
annotated fold change results for each model using
TRANSFAC (Additional file 2, 3). For example, for genes
regulated by Neu (Figure 2A), we predicted that a signifi-
cant number of genes had predicted binding sites for the
Krox family of transcription factors (Figure 2B). The
complete results for the transcription factor binding pre-
dictions are included in the additional data for each of the
models.
We also annotated fold change differences between
each model using gene ontologies (Additional files 2,
3). As an example of the utility of the method, we ex-
amined the similarities and differences in gene ontol-
ogies in the Neu and TAG models (Figure 2C). Both
Neu and TAG tumors featured biological processes,
metabolism and nucleic acid-related metabolism as
major ontological categories. Key differences included
Neu tumors with genes related to transport, ion transport
and biosynthesis, categories not found with TAG gene ex-
pression changes. TAG tumors had major ontologies
representing genes involved in cell cycle, cell organization,
cytoskeleton organization and biogenesis, and cell
organization and biogenesis. To expand upon gene ontol-
ogy results we compared each model to all other models
and separately to normal mammary gland using GSEA
(Additional file 11). This analysis predicted unique fea-
tures for all models including specific information on
metabolism, microenvironment, metastasis and possible
pathway activation (Figure 3). For example, TAG tumors
had down regulation of genes significantly enriched for
the citric acid cycle TCA) (Figure 3A). Wnt tumors were
predicted to have upregulation of tumor angiogenesis
(Figure 3B). Not surprisingly, polyoma middle T
(PyMT) tumors show enrichment for gene sets that pre-
dict metastasis (Figure 3C). Finally, GSEA results predicted
that p53 mutant tumors may have increased TNF signaling
activity (Figure 3D). Together, these results provide a cata-
logue of possible important features corresponding to the
transcriptional outcomes of an initiating oncogene event.
Pathway analysis
To expand the predictive analysis, we utilized a gene sig-
nature approach to predict pathway activation across
mouse mammary tumors. The pathway prediction rela-
tionships between the various models were organized
with unsupervised hierarchical clustering (Figure 4). Using
this approach, we noted a large degree of heterogeneity
within models. Myc tumors showed extensive variation in
pathway activation profiles, spanning the spectrum of
Figure 1 Analysis of relationships between mouse mammary tumor models. (A) The unsupervised hierarchical clustering analysis of gene
expression data for mouse mammary tumors, cell types and normal mammary gland is shown. The dendrogram across the top illustrates
relationships between samples and is color-coded to itemize the four main clusters. Below the dendrogram, black bars label samples from each
corresponding model on the same line. Gene expression values are illustrated with the heatmap, according to the scale shown. The vertical dendrogram
beside the heatmap illustrates genes with similar patterns of expression across the samples in the dataset. (B) The pie chart illustrates the gene ontologies of
the genes that are significantly (q = 0, fdr = 0) over-expressed as identified by SAM in the blue cluster of tumors compared to tumors in other clusters. (C) The
gene set enrichment plot comparing tumors from cluster 4 (black) to tumors in the other clusters shows significant enrichment for high expression of a gene
set that defines mesenchymal breast cancer (P= .004). SAM, significance analysis of microarrays.
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pathway activity within each model, we viewed the pathway
predictions on a model-by-model basis (Additional file 12).
For example, in PyMT induced tumors, there is a significantdifference in predicted pathway activity between tumors
from a FVB and AKXD genetic background (Additional file
13). Myc induced tumors with an EMT or squamous hist-
ology had distinct predicted pathway activities relative to
Figure 2 Fold change analysis of Neu induced tumors compared to other tumor models. (A) The expression pattern for the top 50
significantly (q = 0, fdr = 0) upregulated and down regulated genes for Neu-induced tumors as identified by SAM are illustrated with the heatmap.
Above the heatmap, black bars denote the model each sample corresponds to. Expression levels are depicted according to the colorbar beside
the heatmap. (B) The bar graph shows the bayes factor measuring the enrichment of predicted binding sites for the Krox family of transcription
factors within upregulated genes from each model. The dotted line indicates a bayes factor of 2.0. (C) Gene ontologies for upregulated genes in
Neu induced tumors are depicted in the pie chart according to the color-coded categories. (D) Gene ontologies for upregulated genes in TAG
induced tumors are depicted in the pie chart according to the listed color-coded categories. SAM, significance analysis of microarrays; TAG,
large T antigen.
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file 14). In Neu-induced tumors, we observed a major differ-
ence in predicted pathway activity between Neu tumors
using the MMTV promoter and a Tet-on system to drive
oncogene expression (Additional file 15). Taken to-
gether, these data demonstrate that tumor type, geneticbackground, and promoter result in key differences in
pathway activity.
To validate and illustrate the utility of pathway activa-
tion predictions for developing hypotheses about pathways
that function in tumor progression, we identified models
with clear pathway activity predictions. Previous genetic
Figure 3 Gene set enrichment analysis of mouse mammary tumor models. (A) Gene set for genes involved in the TCA cycle are
significantly enriched (P < .0001) for low expression in TAG tumors. (B) A gene set for genes upregulated during tumor angiogenesis are
significantly enriched (P = .019) for high expression in Wnt induced tumors. (C) A gene set for genes upregulated in breast cancer metastasis is
significantly enriched (P = .02) for high expression in PyMT induced tumors. (D) A gene set for genes that upregulated as a result of TNF signaling
is significantly enriched (P < .0001) for high expression in p53 mutant tumors. PyMT, polyoma middle T; TAG, large T antigen; TCA, the citric
acid cycle.
Hollern and Andrechek Breast Cancer Research 2014, 16:R59 Page 7 of 16
http://breast-cancer-research.com/content/16/3/R59studies that correlate with these predictions are noted
(Table 2). Demonstrating the validity of the gene signa-
tures, we observe a large degree of agreement between
pathways with predicted activity and results from previous
investigations.
Comparisons to human breast cancer
With identification of pathways that function in tumor
progression in mouse models, it is important to under-
stand whether the given model is reflective of humanbreast cancer. To this end, we combined datasets for hu-
man breast cancer and the mouse mammary tumors in
our database, removing both batch and platform effects
(Additional file 16). To investigate the relationships be-
tween the mouse mammary tumors and human breast
tumors, we used unsupervised hierarchical clustering.
We identified a large number of mouse mammary tumor
models that had similarities in gene expression profiles
to human breast cancer (Figure 5). Importantly, Myc
and Met induced tumors both recapitulate the
Figure 4 Unsupervised hierarchical clustering of pathway activation predictions in mouse mammary tumors. The dendrogram across the
top illustrates the relationship between samples based on predicted pathway activation profiles. Below the dendrogram, the black bars mark
tumor samples corresponding to the model listed on the same line. The heatmap illustrates the probability of pathway activation according to
the color bar provided below the heatmap. The vertical dendrogram beside the heatmap illustrates pathways with similar predicted activity
across the samples in the dataset.
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histological annotations, specific relationships between
Myc tumor types and human breast cancer subtypes
were observed (Additional file 17). For example, Myc tu-
mors with an EMT histology clustered together with hu-
man claudin low breast cancer. Extending this to the
cluster of tumors predicted to have mesenchymal geneexpression features (Figure 1C), we observed that a large
majority of these tumors also clustered with claudin low
breast cancer. Importantly, further investigation of these
tumors matched marker expression for claudin low tu-
mors (Additional file 18A-K). Together these data dem-
onstrated that there are mouse models that share human
breast cancer heterogeneity with individual tumor types
Table 2 Validation of pathway predictions
Model Pathway Effect References
APC cKO B-Catenin Demonstrated high activation of β-catenin signaling in these tumors. [65]
APC cKO Myc High levels of Myc demonstrated by IHC in these mammary tumors. [65]
BRCA & P53 mut EGFR Using IHC, EGFR was shown to be overexpressed in this mouse model. [68]
DMBA Ras Observation of H-Ras mutations in mammary hyperplastic outgrowths after
treatment with DMBA.
[69]
DMBA EGFR Using western blot and IHC, EGFR signaling was shown to be active in DMBA
induced mammary tumors.
[70]
ETV6-Ntrk3 Src ETV6-Ntrk3 binds to and activates c-Src, and inhibition of c-Src activation
blocks EN transforming activity using mouse engineered mouse embryonic
fibroblasts.
[71]
Myc Ras Activating mutations in K-Ras found in a subset MMTV-Myc induced tumors
with a predicted elevation of Ras signalling.
[15]
Myc B-Catenin IHC analysis demonstrates higher expression of B-Catenin in the microacinar
histology of Myc driven tumors.
[15]
Myc E2F1 E2F2 E2F3 E2F loss altered tumor latency and Myc proliferative effects on the mammary
gland.
[20]
Neu Akt Akt loss effects tumor development in the MMTV-Neu mouse model. [72]
Neu B-Catenin Using a beta-gal reporter, ß-catenin/TCF-dependent transcription was shown
to be elevated in MMTV-Neu mouse mammary glands.
[73]
Notch B-Catenin Knocking down Notch in a human breast cancer cell line also impacted levels
of beta-catenin.
[74]
PyMT Tgfb Blockade of TGF-beta inhibits mammary tumor metastasis. [75]
PyMT Src Loss of c-Src greatly reduced the occurrence of mammary tumors in the
MMTV-PyMT mouse model.
[76]
Tag Ras K-ras amplifications observed in large t-antigen mediated tumorigeneis. [77]
Tag E2F2 E2F3 RB KO Large T Antigen simulates loss of Rb by leading to deregulated acitvation
of the E2F transcription factors.
[78]
Wnt p53 MMTV-Wnt1 mammary tumors with mutant p53 exhibited a superior clinical
response compared to tumors with wild-type p53.
[79]
DMBA, 7,12-dimethylbenz[a]anthracene; EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; MMTV, mouse mammary tumor virus; PyMT,
polyoma middle T; TGF, transforming growth factor.
Hollern and Andrechek Breast Cancer Research 2014, 16:R59 Page 9 of 16
http://breast-cancer-research.com/content/16/3/R59that are closely related to subsets of human breast can-
cer at the level of gene expression.
In addition to comparing mouse mammary tumors and
human breast cancer with gene expression, we tested rela-
tionships using pathway activation predictions. Using a
mixture modeling approach, we clustered human breast
cancer into ten different groups based on pathway activa-
tion profiles (Figure 6). The pie chart above each heatmap
shows the spectrum of the intrinsically annotated samples
in each group. No single group was made up of one intrin-
sic subtype, illustrating the heterogeneity of pathway acti-
vation within and between intrinsic subtypes of breast
cancer. After groups of human tumors were identified, the
probability that an individual mouse mammary tumor
belonged to a group of human breast cancer was calcu-
lated using the pathway activation profile of the mouse
mammary tumor sample. Observing these probabilities
with a heatmap, we noted that no single group of human
breast cancer was modeled by a single mouse mammary
tumor type at the pathway level. Instead, for each group ofhuman breast cancer, multiple mouse models showed simi-
lar predicted pathway activation profiles. Further, these re-
sults demonstrated that mouse model relationships to
human breast cancer extended beyond the initiating onco-
gene. For example, mouse tumors initiated by Myc overex-
pression contained several different tumor types, each
modeling a different group of human breast cancer includ-
ing those groups that have lower predicted Myc activity.
Moreover, Neu initiated tumors using an inducible pro-
moter frequently model a single group of human breast
cancer (Additional file 19), while other Neu models have
diverse pathway activation profiles leading to relationships
with several different groups of human breast cancer.
These results considered together highlight the similarity
and differences between mouse models and human breast
cancers.
Discussion
Here we have described the genomic analysis of a dataset
composed of publicly available gene expression data for
Figure 5 Unsupervised hierarchical clustering of mouse mammary tumor and human breast cancer gene expression data. Across the
top, the dendrogram illustrates the relationship between human and mouse tumor samples on the basis of gene expression profiles. The red
bars mark the intrinsic subtype of each human tumor sample according the annotation on the same line. The blue bars correspond to the
mouse mammary tumor type. Below this, a heatmap shows the gene expression patterns for each sample, with expression values illustrated
according to the color bar on the right. The dendrogram beside the heatmap shows the correlation between genes based on expression
patterns across the samples in the dataset.
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lyzed through a variety of mechanisms to ask how mouse
models are distinct, what properties they share and how
they reflect human breast cancer. These data indicate that
great care should be taken to appropriately choose the
mouse model to use and that a genomic and histological
characterization of tumors should be completed following
experimentation.
In the examination of mouse models in the database,
unsupervised hierarchical clustering revealed significant
heterogeneity both between models and within modelsand was pronounced in tumor models with a large num-
ber of samples. Between model differences were fully ex-
pected given the unique initiating events causing tumor
formation. However, prior studies with relatively few
samples for each model did not demonstrate extensive
within model heterogeneity [18]. In comparison, we have
demonstrated extensive heterogeneity within many models.
In part this is due to differences between intrinsic clustering
methods [80] and unsupervised hierarchical clustering. How-
ever, given that we have noted corresponding differences in
fold change, GSEA predictions and pathway signature
Figure 6 Mixture modeling analysis of human breast cancer pathway heterogeneity and relationships to mouse models of breast
cancer. Pie charts above each heatmap illustrate the distribution of the intrinsic subtype of samples in each group, according to the color-coded
legend. The heatmap for groups 1 to 10 shows predicted pathway activity with probabilities corresponding to the color bar at the bottom of the
figure. Below this, black bars mark the samples corresponding to annotations on the same line. Following the samples down to the heatmap
below the black bars, the probability that a mouse model has similar pathway activation profiles is shown for each group. Probabilities for this
heatmap are shown according to the color bar at the bottom of the figure.
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of samples used in the analysis. As such, this provides an im-
portant caution to characterize a sufficiently large population
of tumors to capture heterogeneity in the analysis.
Given that there is typically a predominant histological
pattern associated with a given GEM tumor type [81], it is
not surprising that there is a predominant genomic pat-
tern. Indeed, we noted for many models that histology
is predictive of the genomic subtype. Interestingly, thishistological and genomic interaction is capable of spanning
tumor initiating events from different mouse models. In-
deed, EMT and spindle-type tumors from diverse models
clustered together and were distinct from the non-EMT
samples originating in the same model system. Thus, it is
also critical for investigators to analyze all tumors from a
given model for both histological and genomic patterns.
Mouse models were also investigated individually in com-
parison to the entire dataset using a variety of methods. This
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change level, specific GSEA enrichment effects and key
pathway signature differences. In many cases, these results
correlated with prior studies. For instance, annotation of fold
change results predicted that Neu induced tumors upregu-
lated Krox 20 which is consistent with previous chromatin
immunoprecipitation (ChIP) results [82]. When pathway
signatures were examined, there were a large number
of predictions that could be made for pathways used in
specific GEM tumor models. Importantly, while these
pathway signatures have previously been validated [2],
the model by model pathway predictions shown in
Table 2 are highly consistent with previously published
tests. For instance, the pathway signatures predicted a
high probability of Src activation in PyMT tumors in
the FVB background and recent work has demonstrated
the necessity for c-Src in PyMT induced tumors [76]. Col-
lectively, for the pathways listed in Table 2, we note agree-
ment between the pathway signature predictions and the
reported genetic crosses. Moreover, the pathway signature
predictions are also reflective of additional mutations that
accumulate in the samples. This was noted in the Myc
and TAG induced tumors where the Ras signature was
predicted to be elevated, consistent with the large number
of Ras activating mutations in these strains [15,77]. Given
that numerous published genetic tests are in agreement
with the pathway predictions, the remaining cell signaling
pathway predictions offer a large number of testable hy-
potheses. In the future, pathway predictions in the various
models should prove to be an important resource for initi-
ating studies into investigating the importance of various
signaling pathways in tumor biology.
One of the key aspects of this study was the compari-
son between mouse models and human breast cancer.
These data demonstrated similarities and differences be-
tween the two groups and should serve as an important
consideration when attempting to extend the compari-
son of mouse models to human cancer. Taking into ac-
count the clustering data, we readily noted that the
heterogeneity between human breast cancer samples
was present within individual mouse models. Despite
capturing the genomic diversity of the samples, we noted
several samples with no genomic similarity to human
breast cancer, including tumors from strains with other
samples that had clear similarity to human breast cancer.
This clearly suggests that if conclusions are to be drawn
from mouse models of breast cancer, that the mouse
samples should be compared and clustered with a variety
of human tumors.
In addition to clustering of genomic data, we com-
pared mouse models to human breast cancer through
signaling pathway activation predictions. These results
showed that for any given group of human breast cancer
samples, there was a mouse model with similar pathwayactivation profiles. Using these results, it is possible to
select the mouse model that most closely represents a
group of human breast cancer for the signaling pathways
of interest. However, it is critical to consider both clus-
tering and pathway activation and to combine these
methods to choose the most appropriate model to mimic
human breast cancer. For example, to model HER2+
breast cancer and to study the role of HER2 in tumor de-
velopment, research initially used the MMTV-Neu mice
[7]. However, the gene expression data reveals that this
strain does not associate with the HER2+ human samples
through genomic clustering. However, mixture modeling
indicated that a proportion of HER + human cancers did
group with the MMTV-Neu samples at the level of path-
way activation. This indicates that in some aspects the
mouse model is appropriately related to human HER2+
breast cancer. Further, recent reports demonstrate that a
strain of mice with conditional activation of Neu under
the control of the endogenous promoter which undergo
amplification [8] far more closely recapitulate human
HER2+ breast cancer [21]. Taken together, these data il-
lustrate the importance of fully characterizing and using
all genomic information to select the appropriate model
for examination.
Recent reports have described the development of seri-
ally transplantable human breast cancer samples that are
grown in a murine host with clear genomic similarity to
the primary human breast cancer samples [83] and obvi-
ously this is an optimal model for specific studies. How-
ever, there is clear utility for GEM models, especially
with regard to the ability to ask defined genetic questions
with regard to key signaling pathways in tumor biology.
As such, the prior characterization of mouse and human
breast cancer similarities was a critical development [18].
The expanded number of samples and methods of analysis
in this report have clearly illustrated additional compo-
nents of mouse breast cancer biology that require careful
consideration. Indeed, the extent of genomic heterogen-
eity was only appreciated previously for select models
[11,15-17], but our work indicates that this is a general
characteristic across the majority of breast cancer model
systems. As such, this work underscores the requirement
to fully characterize mouse tumor biology at histological
and genomic levels before a valid comparison to human
breast cancer may be drawn. Thus, we have provided the
complete files for all of the comparisons made in this
manuscript, from fold change between models to GSEA
and pathway predictions, with the intent of this being used
as a resource to choose and compare mouse models in
breast cancer research.
Conclusions
Collectively, our work demonstrates genomic heterogen-
eity in mouse mammary tumor models. As an additional
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predictive resource for each of the mouse models in the
database. With heterogeneity driving a variety of rela-
tionships between individual mouse mammary tumors
and human breast cancer, this work highlights the neces-
sity of fully characterizing mouse tumor biology at mo-
lecular, histological and genomic levels before a valid
comparison to human breast cancer may be drawn.Additional files
Additional files 1, 2, 3, 6, 7, 11, 12 are available for
download at: https://www.msu.edu/~andrech1/BCR_
Supplemental/BCR_Supplemental.html. The results of
each analysis are provided as links to zipped folders
as described below and are numbered according to their
reference in the manuscript. Clicking on a link will begin
the download of the zipped material.
Additional file 1: PCA code for Matlab.
Additional file 2: Fold change values organized by mouse tumor
model type comparing the mouse model to all other types of
mouse models.
Additional file 3: Fold change values organized by mouse tumor
model type comparing the mouse model to normal mammary
gland.
Additional file 4: Table S1. Gene signature settings for pathway
predictions. Specific settings are shown for each gene signature of
pathway activation.
Additional file 5: Figure S1. Removal of Batch Effects from Affymetrix
Datasets. (A) Affymetrix datasets color coded according to the study of
origin in a principle components analysis plot prior to BFRM batch effect
correction. (B) Affymetrix datasets color coded according to the study of
origin in a principle components analysis plot after BFRM batch effect
correction. (C) Affymetrix datasets are color coded together in blue after
BFRM batch effect correction. The various Agilent gene expression
datasets are color-coded and plotted along with Affymetrix data on the
three principle components to illustrate platform and batch variance. (D)
Agilent and Affymetrix color-coded data plotted after COMBAT removed
batch and platform technical variance. (E) Neu-induced tumors are color
coded in blue and all other tumors are in green, illustrating variance
between similar tumor types on the basis of platform and batch artifacts. (F)
Neu-induced tumors are color coded in blue and all other tumors are in
green illustrating mediation of batch and platform effects.
Additional file 6: Fold change for genes in clusters 1-4 from the
manuscript and the gene ontology associated with each cluster.
Additional file 7: GSEA for clusters 1-4, each of the runs (C2, C3,
and so on) is in a separate folder.
Additional file 8: Figure S2. Gene set enrichment analysis for mouse
mammary tumors in the black color-coded cluster. (A) A gene set for
down regulated genes in mesenchymal breast cancer is significantly
enriched (P <.0001) and down regulated in the black cluster (cluster4)
of tumors. (B) A gene set for Zeb1 target genes is significantly
enriched (P = .005) for low expression for the tumors in the black
cluster. (C) A gene set for genes highly expressed in mammary stem
cells is significantly enriched (P = .016) and upregulated in tumors
from cluster 4 (black). (D) A gene set for genes that are down
regulated in mammary stem cells is significantly enriched (P <.0001)
and also down regulated in the cluster 4 (black) tumors.
Additional file 9: Figure S3. Tumors that were classified for
mesenchymal histology cluster into the black cluster. Highlighting prior
histological annotations for mesenchymal or EMT-like tumors across theMyc, IGF-IR, DMBA, and p53 mutant models show that a large majority of
these tumors cluster together in the black cluster.
Additional file 10: Figure S4. Gene set enrichment analysis for
mammary cell types across major clusters of mouse mammary tumors.
GSEA for tumors in blue cluster compared to all other clusters show
significant enrichment for a mammary luminal progenitor cell gene
expression signature (P = .006). Similarly, tumors from the green cluster
associate with a mixture of luminal cell gene expression features, while
tumors in the orange cluster are significantly enriched for gene
expression features of mature luminal cells (P = .04). Lastly, tumors in the
black cluster are significantly enriched for gene expression features of
mammary stem cells (P = .01).
Additional file 11: GSEA for mouse models compared to all other
models or to mammary gland development. Listed by model.
Additional file 12: PDFs of pathway predictions for each mouse
model of breast cancer, folders exist for each mouse modelx.
Additional file 13: Figure S5. Unsupervised hierarchical clustering of
pathway probabilities for PyMT induced tumors. The dendrogram across
the top illustrates the relationship between PyMT tumor types on the
basis of pathway activation profiles. Below the dendrogram black bars
correspond to sample details on the same line, annotating the genetic
background and sample type for each sample. The heatmap shows the
predicted pathway activity according to the probabilities listed on the
color bar below the heatmap. Directly beside the heatmap, a vertical
dendrogram illustrates the degree of correlation between pathways
across the samples.
Additional file 14: Figure S6. Unsupervised hierarchical clustering of
pathway probabilities for Myc induced tumors. The dendrogram across
the top illustrates the relationship between Myc tumor types on the basis
of pathway activation profiles. Below the dendrogram black bars
correspond to sample details on the same line, annotating the tumor
histology (if known), specific form of Myc expression, recurrence status,
and additional modifications. The heatmap shows the predicted
pathway activity according to the probabilities listed on the color bar
below the heatmap. Directly beside the heatmap, a vertical dendrogram
illustrates the degree of correlation between pathways across the
samples.
Additional file 15: Figure S7. Unsupervised hierarchical clustering of
pathway probabilities for Neu induced tumors. The dendrogram across
the top illustrates the relationship between Neu tumor types on the basis
of pathway activation profiles. Below the dendrogram black bars
correspond to sample details on the same line, annotating the specific
form of Neu, and additional modifications. The heatmap shows the
predicted pathway activity according to the probabilities listed on the
color bar below the heatmap. Directly beside the heatmap, a vertical
dendrogram illustrates the degree of correlation between pathways
across the samples.
Additional file 16: Figure S8. Removal of batch effects between
mouse and human breast cancer datasets. (A) Mouse (blue) and human
(green) Affymetrix data gene expression variance plotted onto three
principle components prior to BFRM. (B) Mouse (blue) and human
(green) Affymetrix data gene expression variance plotted onto three
principle components after BFRM. (C) Human(green) and mouse (blue)
Affymetrix data after BFRM correction put together with mouse Agilent
data (red) prior to COMBAT. (D) Human(green) and mouse (blue)
Affymetrix data after BFRM correction put together with mouse Agilent
data (red) after COMBAT artifact correction.
Additional file 17: Figure S9. Unsupervised hierarchical clustering of
Myc mouse mammary tumors and human breast cancer gene expression
data. Across the top, the dendrogram illustrates the relationship between
human and mouse tumor samples on the basis of gene expression
profiles. The red bars mark the intrinsic subtype of each human tumor
sample according to the annotation on the same line. The blue bars
correspond to the Myc mouse mammary tumor type. Below this, a
heatmap shows the gene expression patterns for each sample, with
expression values illustrated according to the color bar on the right. The
dendrogram beside the heatmap shows the correlation between genes
based on expression patterns across the samples in the dataset.
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http://breast-cancer-research.com/content/16/3/R59Additional file 18: Figure S10. Claudin low marker expression in the
black cluster mouse mammary tumors. Claudin low marker expression
comparisons for cluster 4 (black) tumors compared to tumors in all other
clusters as defined by Figure 1A. (A-C) Cell adhesion markers that have
low expression in claudin low human tumors are also down regulated in
cluster 4 (black tumors), P <.0001. (D-E) Genes that are involved with the
immune system that are found to be highly expressed in claudin low
human tumors are highly expressed in mouse cluster 4 tumors (black),
P <.01 for CD79B and P <.0001 for VAV1. (F) Chemokine (C-X-C motif)
ligand 12, involved in cell communication and previously shown to be
highly expressed in claudin low tumors, is upregulated in cluster 4
(black) mouse mammary tumors, P <.0001. (G) Fibroblast growth
factor 7, an extracellular matrix related factor and previously shown to
be highly expressed in claudin low tumors, is upregulated in cluster 4
(black) mouse mammary tumors, P <.0001. (H-J) Cell migration
markers previously shown to be highly expressed in human claudin
low tumors are upregulated in mouse cluster 4(black) tumors, P <.02
for moesin and P <.0001 for integrin α5. (K) Angiogenesis marker,
VEGFC, was previously shown to be upregulated in human claudin
low tumors and is highly expressed in mouse cluster 4(black) tumors.
Additional file 19: Figure S11. Mixture modeling highlighting pathway
relationships between human breast cancer and specific models of Neu
mediated tumorigenesis. Pie charts above each heatmap illustrate the
distribution of the intrinsic subtype of samples in each group, according
to the color-coded legend. The heatmap for groups 1 to 10 show
predicted pathway activity with probabilities corresponding to the color
bar at the bottom of the figure. Below this, blue bars mark the samples
corresponding to annotations on the same line. Following the samples
down to the heatmap below the blue bars, the probability that a specific
type of Neu model has similar pathway activation profiles is shown for
each group. Probabilities for this heatmap are shown according to the
color bar at the bottom of the figure.
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